Literature DB >> 33977563

Molecular properties prediction, synthesis, and antimicrobial activity of bis(azolyl)sulfonamidoacetamides.

Siva Sankar P1, Narendra Babu K1, Tamatam Rekha1, Adivireddy Padmaja1, Venkatapuram Padmavathi1.   

Abstract

A library of bis(azolyl)sulfonamidoacetamides was prepared by the reaction of azolylsulfonylamines with azolylchloroacetamides in the presence of pyridine/4-(dimethylamino)pyridine (DMAP) under ultrasonication. The reaction proceeded well with DMAP, resulting in a higher yield of the products. The antimicrobial activity of the compounds indicated that N-{5-[N-(2-{[4-(4-chloro-1H-pyrrol-2-yl)-1H-imidazol-2-yl)amino}-2-oxoethyl)sulfamoyl]-4-phenylthiazol-2-yl}benzamide (22a), N-{5-[N-(2-{[4-(4-chloro-1H-pyrrol-2-yl)-1H-imidazol-2-yl]amino}-2-oxoethyl)sulfamoyl]-4-(4-chlorophenyl)thiazol-2-yl}benzamide (22c), and N-{5-[N-(2-{[4-(4-chloro-1H-pyrrol-2-yl)-1H-imidazol-2-yl]amino}-2-oxoethyl)sulfamoyl]-4-(4-chloro-phenyl)-1H-imidazol-2-yl}benzamide (24c) exhibited a low minimal inhibitory concentration (MIC) against Bacillus subtilis, equal to the standard drug, chloramphenicol. Compounds 22c and 24c also showed low MICs against Aspergillus niger, equal to the standard drug, ketoconazole. The molecular properties of the synthesized molecules were studied to identify druglikeness properties of the target compounds. On the basis of molecular properties prediction, 19a, 19b, 20b, 20c, 21a-c, 22b, 22c, and 23a-c can be treated as drug candidates.
© 2021 Deutsche Pharmazeutische Gesellschaft.

Entities:  

Keywords:  antibacterial activity; antifungal activity; bis(azolyl)sulfonamidoacetamides; molecular properties; ultrasonication

Mesh:

Substances:

Year:  2021        PMID: 33977563     DOI: 10.1002/ardp.202000483

Source DB:  PubMed          Journal:  Arch Pharm (Weinheim)        ISSN: 0365-6233            Impact factor:   3.751


  1 in total

1.  Improving Antimicrobial Activity and Physico-Chemical Properties by Isosteric Replacement of 2-Aminothiazole with 2-Aminooxazole.

Authors:  Martin Juhás; Andrea Bachtíková; Daria Elżbieta Nawrot; Paulína Hatoková; Vinod Sukanth Kumar Pallabothula; Adéla Diepoltová; Ondřej Janďourek; Pavel Bárta; Klára Konečná; Pavla Paterová; Vít Šesták; Jan Zitko
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.